Laboratory products
GLP-1R reporter cell line advances diabetes and obesity research
Jul 02 2024
AMSBIO has introduced a new Glucagon-Like Peptide 1 Receptor (GLP-1R) reporter cell line, designed to advance research in diabetes and obesity. GLP-1R plays a crucial role in blood sugar regulation by enhancing glucose-stimulated insulin secretion, making it a key target for type 2 diabetes treatments. The regulation of the GLP-1R signalling pathway has led to the development of several FDA-approved GLP-1 agonists. Additionally, GLP-1R agonists aid in weight management, reduce cardiovascular disease risk, and protect pancreatic beta cells.
The new GLP-1R/CRE Luciferase Reporter HEK293 cell line measures luciferase activity to monitor GLP-1R activation in cells. This cell line is ideal for cell-based binding assays and screening human GLP-1R agonists. Its functionality has been validated in dose-response assays with both peptide and small molecule agonists.
AMSBIO has also launched gastric inhibitory polypeptide receptor (GIPR) and glucagon receptor (GCGR) reporter cell lines to complement the GLP-1R cell line. These receptors are vital for blood sugar regulation, and dual agonists targeting GIPR/GCGR and GLP-1R show promise for type 2 diabetes and obesity treatments. Together, these cell lines offer a robust platform for screening combination therapies by measuring the activity of co-stimulatory targets in response to agonists.
To assist investigations into muscle loss caused by GLP-1R agonists, AMSBIO also offers a range of skeletal muscle research products.
More information online
Digital Edition
Lab Asia 31.6 Dec 2024
December 2024
Chromatography Articles - Sustainable chromatography: Embracing software for greener methods Mass Spectrometry & Spectroscopy Articles - Solving industry challenges for phosphorus containi...
View all digital editions
Events
Jan 22 2025 Tokyo, Japan
Jan 22 2025 Birmingham, UK
Jan 25 2025 San Diego, CA, USA
Jan 27 2025 Dubai, UAE
Jan 29 2025 Tokyo, Japan